Chaperon announced on the 2nd that it will participate in the '2025 JP Morgan Healthcare Conference' (hereinafter referred to as the JPM Conference), the world's largest pharmaceutical and biotech event. At this event, Chaperon is expected to initiate active discussions on technology transfer with numerous global pharmaceutical companies, focusing on the clinical outcomes of NuGel, an atopic dermatitis treatment.
The JPM Conference will be held from the 13th to the 16th of this month in San Francisco, USA. It is the largest and most influential healthcare investment conference attended by key decision-makers in the global healthcare and life sciences industries. Every year, about 10,000 top executives from approximately 450 global pharmaceutical, biotech, and corporate entities worldwide gather to share new drug research and development (R&D) achievements and status, and to discuss technology cooperation and licensing out (L/O).
At this event, Chaperon plans to meet with several global pharmaceutical and biotech companies to introduce its major pipelines and engage in in-depth discussions for technology transfer. In particular, many companies that have shown interest at overseas conferences are scheduled to meet regarding the Part 1 clinical results of NuGel, an atopic dermatitis treatment currently undergoing Phase 2b clinical trials in the United States.
NuGel is the world's first atopic dermatitis treatment with a mechanism that inhibits the inflammasome complex. Unlike existing inflammasome inhibitors that suppress the activation stage of inflammation, NuGel acts doubly at both the initiation and amplification stages of inflammation, enabling effective inflammation control. NuGel demonstrates an anti-inflammatory effect comparable to steroid preparations but does not show side effects such as immunosuppression, allowing for long-term use. Accordingly, it is expected to become an effective treatment alternative for patients with mild to moderate atopic dermatitis.
The Part 1 of the Phase 2b clinical trial of NuGel, conducted in the United States, is a clinical study involving diverse ethnic groups including Caucasians, and allows for safety and efficacy analysis by dosage, attracting attention from global pharmaceutical companies. Chaperon plans to proceed to the full-scale Part 2 clinical trial after the Safety Monitoring Committee (SMC) review of Part 1 in early January next year.
A Chaperon official stated, “We have completed recruitment of all patients scheduled for Part 1 and successfully finished dosing,” adding, “No serious adverse events were observed in any dosing group even under double-blind conditions, so we expect smooth progress into the Part 2 clinical trial.”
He continued, “Through active sales activities at overseas events such as the BFC Conference and JPM Conference, we will achieve technology transfer results for major pipelines including NuGel,” emphasizing, “At the same time, we will accelerate R&D for each pipeline to fully commercialize the company’s revenue generation.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
